Marktanalyse - Rhino-Conjunctivitis - Pipeline Review, H2 2016

Global Markets Direct
12.2016
81 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Rhino-Conjunctivitis - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhino-Conjunctivitis — Pipeline Review, H2 2016, provides an overview of the Rhino-Conjunctivitis (Ophthalmology) pipeline landscape.

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 3, 5, 8, 3 and 1 respectively.

Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Rhino-Conjunctivitis Overview 8

Therapeutics Development 9

Pipeline Products for Rhino-Conjunctivitis - Overview 9

Rhino-Conjunctivitis - Therapeutics under Development by Companies 10

Rhino-Conjunctivitis - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Rhino-Conjunctivitis - Products under Development by Companies 14

Rhino-Conjunctivitis - Companies Involved in Therapeutics Development 15

ALK-Abello A/S 15

Allergy Therapeutics Plc 16

ASIT Biotech SA 17

Astellas Pharma Inc 18

Bial - Portela & Ca SA 19

Circassia Pharmaceuticals Plc 20

Griffin Discoveries BV 21

HAL Allergy BV 22

Laboratorios LETI SL 23

Oxagen Ltd 24

Roxall Medizin GmbH 25

Stallergenes Greer plc 26

Rhino-Conjunctivitis - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Combination Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Allergen for Allergic Rhino-Conjunctivitis - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Allergovac - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ASP-4070 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

clustoid wiesenlieschgras - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

gp-ASIT - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

hdm-ASIT - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

OC-2417 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Pollinex Quattro Grass - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Timapiprant - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Rhino-Conjunctivitis - Dormant Projects 70

Rhino-Conjunctivitis - Discontinued Products 72

Rhino-Conjunctivitis - Product Development Milestones 73

Featured News & Press Releases 73

Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study 73

Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen 74

May 18, 2014: BioTech Tools will be present at the EAACI congress 75

Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology 76

Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics 77

Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites 78

Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA 78

Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study 79

Appendix 80

Methodology 80

Coverage 80

Secondary Research 80

Primary Research 80

Expert Panel Validation 80

Contact Us 80

Disclaimer 81





List of Tables

Number of Products under Development for Rhino-Conjunctivitis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H2 2016 15

Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H2 2016 16

Rhino-Conjunctivitis - Pipeline by ASIT Biotech SA, H2 2016 17

Rhino-Conjunctivitis - Pipeline by Astellas Pharma Inc, H2 2016 18

Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca SA, H2 2016 19

Rhino-Conjunctivitis - Pipeline by Circassia Pharmaceuticals Plc, H2 2016 20

Rhino-Conjunctivitis - Pipeline by Griffin Discoveries BV, H2 2016 21

Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H2 2016 22

Rhino-Conjunctivitis - Pipeline by Laboratorios LETI SL, H2 2016 23

Rhino-Conjunctivitis - Pipeline by Oxagen Ltd, H2 2016 24

Rhino-Conjunctivitis - Pipeline by Roxall Medizin GmbH, H2 2016 25

Rhino-Conjunctivitis - Pipeline by Stallergenes Greer plc, H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Assessment by Combination Products, H2 2016 28

Number of Products by Stage and Target, H2 2016 30

Number of Products by Stage and Mechanism of Action, H2 2016 32

Number of Products by Stage and Route of Administration, H2 2016 34

Number of Products by Stage and Molecule Type, H2 2016 36

Rhino-Conjunctivitis - Dormant Projects, H2 2016 70

Rhino-Conjunctivitis - Dormant Projects (Contd..1), H2 2016 71

Rhino-Conjunctivitis - Discontinued Products, H2 2016 72





List of Figures

Number of Products under Development for Rhino-Conjunctivitis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Targets, H2 2016 29

Number of Products by Stage and Targets, H2 2016 29

Number of Products by Mechanism of Actions, H2 2016 31

Number of Products by Stage and Mechanism of Actions, H2 2016 31

Number of Products by Routes of Administration, H2 2016 33

Number of Products by Stage and Routes of Administration, H2 2016 33

Number of Products by Molecule Types, H2 2016 35

Number of Products by Stage and Molecule Types, H2 2016 35

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus